INFORMATION DISCLOSURE CITATION

PTO-1449

ATTORNEY'S DKT NO.	APPLICATION NO.
012712-419	Unassigned
APPLICANT: Nabil HANNA et al.	
FILING DATE: September 18, 1997	GROUP: Unassigned

U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE
GW	5,585,103	12/17/96	Raychaudhuri et al.	424	278.1	07/24/92
GW	5,514,670	05/07/96	Friedman et al.	514	2	08/13/93

FOREIGN PATENT DOCUMENTS

EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	Translation Yes	Translation No
GW	WO94/09815	05/11/94	WO	—	—		

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

GW	Dybedal et al., "Transforming Growth Factor β (TGF-β), A Potent Inhibitor of Erythropoiesis: Neutralizing TGF-β Antibodies Show Erythropoietin as a Potent Stimulator of Murine Burst-Forming Unit Erythroid Colony Formation in the Absence of a Burst-Promoting Activity", *Blood*, 86(3):949-957 (1995).
	Sitnicka et al., "Transforming Growth Factor β_1 Directly and Reversibly Inhibits the Initial Cell Divisions of Long-Term Repopulating Hematopoietic Stem Cells", *Blood*, 88(1):82-88 (1996).
	Jacobsen et al., "Transforming Growth Factor-β Potently Inhibits the Viability-Promoting Activity of Stem Cell Factor and Other Cytokines and Induces Apoptosis of Primitive Murine Hematopoietic Progenitor Cells", *Blood*, 86(8):2957-2966 (1995).
	Clarke et al., "Lisofylline Inhibits Transforming Growth Factor β Release and Enhances Trilineage Hematopoietic Recovery after 5-Fluorouracil Treatment in Mice", *Cancer Research*, 56:105-112 (1996).
	Kopp et al., "Transforming Growth Factor β2 (TGF-β2) Levels in Plasma of Patients with Metastatic Breat Cancer Treated with Tamoxifen[1]", *Cancer Research*, 55:4512-4515 (1995).
	Sansilvestri et al., "Early CD34^{high} Cells Can Be Separated Into KIT^{high} Cells in Which Transforming Growth Factor-β (TGF-β) Downmodulates c-*kit* and KIT^{low} Cells in Which Anti-TFG-β Upmodulates c-*kit*", *Blood*, 86(5):1729-1735 (1995).

EXAMINER	DATE CONSIDERED
Gary Kunz	7/17/03

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.